Search results
Earnings call: SelectQuote sees growth in Medicare Advantage, raises outlook By Investing.com
Investing.com· 7 days agoSelectQuote, Inc. (SLQT) delivered a confident fiscal third-quarter earnings report, emphasizing...
(Toni says) Please simplify Medicare’s enrollment process
Cullman Times· 6 days agoToni: I need to make the right Medicare decision because I turn 65 in August and have not had a...
Man vs. Machine: Federal Employees - Medicare and FEHB
TheStreet.com· 3 days agoMan vs. Machine: ChatGPT tackles FEHB plans & Medicare. Expert critique inside!
Analyst Report: Humana Inc.
Morningstar Research via Yahoo Finance· 2 days agoHumana is one of the largest private health insurers in the US with a focus on administering Medicare Advantage plans. The firm has built a niche specializing ...
Social Security or Medicare: Which Is in the Most Immediate Danger?
Motley Fool via Yahoo Finance· 5 days agoIt comes in two key forms: original Medicare ,which includes Parts A and B, typically with Part D...
HHS Final Section 1557 Nondiscrimination Regulations: Gender-Affirming Care and the Role of Carriers...
The National Law Review· 7 days agoIf Section 1557 applies to carriers and TPAs acting in an ASO capacity for self-funded group health...
Comment: Turning 65? Here’s what to know about Medicare | HeraldNet.com
Everett Herald· 2 days agoWhether this milestone means retirement or not, these individuals need to make important choices about their health care. For many Washington residents, the transition from an employer-sponsored ...
CVS Risks Losing 10% of Medicare Members in Push for Profits
Bloomberg· 3 days agoHave a confidential tip for our reporters? CVS Health Corp. may lose a big chunk of members in its...
Blend Extra: Maximize Medicare, Cancer Insurance, and More!!
TMJ4 Milwaukee· 24 hours agoWith access to dozens of insurance companies and their products, Sovereign Select custom fits your ...
Does Medicare Cover the RSV Vaccine?
US News Health· 3 days agoCDC recommends vaccination for higher-risk populations. Two vaccines – Arexvy and Abrysvo – are currently approved by the FDA for those ages 60 and older and offers protection for two years.
